A Prospective Study to Evaluate the Consistency of Next-Generation Sequencing(NGS)-Panels by Using Malignant Hydrothorax Form NSCLC

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-05-18

Study Completion Date

2019-05-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A prospective study to evaluate consistency of different NGS-panel. Cell free DNA is purified from each malignant hydrothorax from NSCLC .Different NGS-panels are applied to perform in vitro diagnosis to detect Single Nucleotide Variants(SNV) and to calculate TMB value in these DNA samples.Consistency of enrolled NGS-panels are then evaluated by statistical analysis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

NGS-based Comprehensive Genomic ctDNA Panel in NSCLC With Immunotherapy

NCT04636047

Lung Cancer

UNKNOWN

Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy of NSCLC Patients in China

NCT03059641

Lung Neoplasms Lung Cancer, Nonsmall Cell Adenocarcinoma of Lung +1 more

COMPLETED

Exploration on the Value of MRD Based on ctDNA Detection in Predicting Recurrence of Resected Non-small Cell Lung Cancer

NCT05965024

Non-small Cell Lung Cancer

RECRUITING

Whether Sputum Can Serve as an Alternative Source for Liquid Biopsy in Patients With Lung Cancer

NCT05034445

NSCLC

COMPLETED

ctDNA Dynamic Monitoring and Its Role of Prognosis in Stage I NSCLS by NGS

NCT03172156

Non-small Cell Lung Cancer Stage I

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

1. Chest Hospital in accordance with the clinical requirements of the treatment required to extract ML hydrothorax sent to hospital pathology department for exfoliated Cell diagnosis and production of cell wax block, while the additional responsibility for the extraction of hydrothorax 500ml, and collect 10ml venous blood sample, Venous blood samples are stored in either the A cell-free DNA Blood collection Tube (STRECK tube) or the ethylenediaminetetraacetic acid(EDTA) anticoagulant tube.
2. Amoy Diagnostics Co., Ltd. (AmoyDx) is responsible for plasma separation after sampling 2 hours, plasma is frozen by the chest Hospital, AmoyDx completes the purification of peripheral blood cells genomic DNA , and which is divided into 6 parts ,5 of which are send to in vitro diagnostic products (IVD) enterprises to perform NGS-Panel detection.
3. 100ml hydrothorax is send to each IVD enterprise.
4. Each IVD enterprise carries on the hydrothorax cell free DNA and peripheral blood cell genomic DNA NGS-Panel detection according to their own protocol.
5. Each IVD enterprise will complete the test within 7-10 working days and fill out the results in accordance with the report template provided by this research project (provided by Guangzhou Burning Rock Medical Examination Institute Co., Ltd.) and submit to sponsor by email.
6. Sponsor would use whole exon panel (WES) to obtain an TMB value if needed.
7. Employ four-grid analysis to evaluate positive compliance rate, negative compliance rate, total compliance rate of all submitted data.
8. Employ kappa test to evaluate the consistency of each two detections.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Malignant Hydrothorax NSCLC

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

malignant NSCLC hydrothorax

cell free DNA ,which is purified from malignant NSCLC hydrothorax, tested by in vitro NGS-panel

in vitro NGS-panel

Intervention Type DIAGNOSTIC_TEST

cell free DNA ,which was purified from hydrothorax, is used to be tested by NGS-panel

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

in vitro NGS-panel

cell free DNA ,which was purified from hydrothorax, is used to be tested by NGS-panel

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Advanced malignant lung cancer, with treatment of pleural effusion, hydrothorax volume not less than 800ml

Exclusion Criteria

* The sample size is not sufficient to detect.
* There are not enough tumor cells in the tissue section to be evaluated through the pathology department of the chest Hospital.

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No